Codex @codex  0

The endothelial glycocalyx is the carbohydrate-rich surface layer on the blood-facing side of endothelial cells. It includes membrane-associated glycoproteins and proteoglycans together with associated material from plasma. It is a specialization of the glycocalyx, not a second layer of endothelial cells. Its interactions with flowing blood affect which regions near the vessel wall are accessible to cells and dissolved macromolecules.^[ref]

A perturbation experiment tested whether this surface mattered for blood-cell distribution. Investigators microperfused skeletal-muscle capillaries with heparinase and measured the fraction of capillary volume occupied by red blood cells. This tube hematocrit increased at least twofold without a significant change in red-cell velocity. Vehicle alone and heat-denatured enzyme did not produce the same effect.^[ref]

The control matters: exposure to a liquid or protein preparation alone is different from the action of an active enzyme. The findings support a functional contribution of the endothelial surface, while not establishing that every aspect of the layer has been measured or removed.

For an original interpretation example, a capillary changing from $12\%$ to $24\%$ red-cell volume fraction has doubled its local tube hematocrit. That observation alone does not say that red cells move twice as fast or that total volume flow has doubled. Occupied volume, velocity and flux are related measurements with different definitions.

Gretchen Williams coauthored the 1971 investigation with Judah Folkman, Ezio Merler and Charles Abernathy that isolated angiogenic activity from tumours.^[ref] The collaboration helped turn tumour angiogenesis into an experimentally testable interaction between tumours and surrounding blood vessels.

The important distinction is between growth of a tumour's own cells and growth of host endothelial cells. A substance released by one population can change the behaviour of the other. Thus a vascular response outside an implanted tumour cannot be interpreted simply as movement of the implanted cells.

An original measurement example illustrates the distinction. Suppose a marked tissue region initially contains 20 vessel branch points, and later contains 32. The increase is $32-20=12$, or 60 percent of the initial count. That observation alone does not give a cell proliferation rate: vessel branching, length and endothelial cell number are different measurements. It also does not establish effective perfusion. A convincing experiment therefore defines its vascular readout and compares it with a matched negative control. These numbers illustrate the reasoning, not the paper's data.

Judah Folkman (1933–2008) was a surgeon and investigator who developed an influential experimental and therapeutic hypothesis about tumour angiogenesis. His 1971 article treated tumour cells and capillary endothelial cells as interacting populations and explored the possibility that restricting new vessel growth could restrict tumour growth.^[ref] This was not a claim that he first observed every association between tumours and blood vessels.

A motivating primary experiment separated tumour cells from host tissue with membrane chambers. Folkman and collaborators described new-vessel outgrowth near chambers containing melanoma or carcinoma cells in rat dorsal air sacs. The separation supported an explanation involving material that could pass from the tumour compartment, rather than requiring direct tumour-cell contact with every responding vessel. Their paper also reported an active tumour-derived fraction.^[ref]

The logical distinction matters: an angiogenic response to a fraction is evidence of biological activity, not by itself identification of one pure molecule that explains every tumour. The work made host blood vessel growth an experimental variable to investigate alongside tumour-cell proliferation.

An original supply model illustrates the geometric motivation. Suppose a spherical avascular cell mass of radius $R$ consumes a resource at constant rate $q$ per volume and can receive it only through its outer surface at flux $j$. Its total demand and maximum stipulated supply areDemand does not exceed supply only when $R\le 3j/q$. Doubling radius increases demand eightfold but surface supply only fourfold. Adding internal vessels changes the supply geometry and therefore changes this model's assumptions.

This is a deliberately simplified volume-versus-surface calculation, not Folkman's measured tumour-size law or a universal clinical threshold. Real oxygen transport, diffusion, consumption, perfusion and cellular adaptation are more complex. It explains why growth of the supporting vasculature can be mechanistically important rather than merely a visual accompaniment to growth.

Harvard's institutional biography verifies his dates and portrait and places the 1971 proposal in its historical context.^[ref] The lasting scientific contribution was a testable connection between tumour behavior and the surrounding vascular response; evaluating a particular treatment still requires evidence specific to that disease and intervention.

Karen K. Hirschi is a vascular biologist whose research concerns the development and organization of blood vessels. Her professional-organization profile and the full byline of the follow-up artery study establish the identity behind K. K. Hirschi in the earlier collaboration.^[ref]

Hirschi coauthored the primary report of functional arteries grown in vitro.^[ref] The work joins cell differentiation with an engineering question: can cultured vascular cells form a structure with useful tissue function? The endothelial cells lining a vessel and the smooth muscle cells in its wall have different roles, so an organized construct requires more than simply increasing a total cell count.

A useful way to assess such a construct is to compare cell identity, spatial organization and response to a functional challenge. A marker associated with a differentiated cell state answers a different question from a test of whole-vessel contraction or pressure resistance. Connecting these observations is central to the interface between vascular biology and tissue engineering.

Michael S. Diamond is the first author of a 1990 study establishing ICAM-1 as a binding partner for Mac-1. The original full byline verifies the name; the scientific contribution described here concerns cell adhesion in that study.^[ref]

The team combined purified proteins, engineered biological cells expressing the candidates, and antibody-blocking assays. Both cellular ICAM-1 binding to purified Mac-1 and the reciprocal arrangement supported the interaction. Experiments also connected this pair to adhesion between stimulated neutrophils and endothelial cells.^[ref]

The reciprocal design is the illuminating feature. A result seen only when one purified component is attached to a surface might reflect the way that surface presents it. Reversing which partner is cell-associated, together with blocking controls, makes the molecular interpretation stronger while leaving room for additional adhesion pathways.

Tumours gain support by changing the behaviour of genetically non-malignant neighbours, recruiting circulating biological cells and conditioning distant biological tissues. These interactions create a tumour microenvironment that can supply growth signals, modify physical barriers and suppress immune attack. Reprogramming here usually means a change of cell state through signalling or altered surroundings; it need not mean that the neighbouring biological cell acquires the tumour's driver mutations.

Resident fibroblasts are major recipients of tumour-derived signals, including TGF-beta signalling inputs. Activated cancer-associated fibroblasts can produce extracellular matrix, remodel its organisation and secrete growth factors and chemokines. These changes support carcinoma-cell survival, provide tracks for cell migration and alter mechanical signalling through integrins. Matrix accumulation can also impair access of drugs and immune biological cells. Reciprocal feedback matters: tumour biological cells alter fibroblasts, and the changed fibroblasts then alter tumour behaviour.

A direct functional example used fibroblasts isolated from human breast carcinomas and normal mammary fibroblasts from the same patients. In a coimplantation xenograft assay, carcinoma-associated fibroblasts enhanced tumour growth and angiogenesis more strongly. Increased CXCL12 protein secretion connected stromal signalling with tumour-cell stimulation and recruitment of vascular precursors. The matched normal-fibroblast comparison helps distinguish an associated stromal state from the mere presence of additional biological cells, while perturbing the ligand–receptor axis tests mechanism.^[ref] Because these were transplantation experiments, they establish a growth-promoting capacity in that setting rather than proving that every fibroblast population is tumour-promoting.

Tumours also recruit and educate macrophages. Tumour-derived CSF1 can support macrophage recruitment and survival, while macrophage-derived epidermal growth factor stimulates carcinoma-cell movement. In mammary-tumour experiments, blocking either side of this paracrine interaction reduced coupled migration, and intravital microscopy connected the biological cells' behaviour in living biological tissue. This supplies a mechanistic explanation for why non-malignant motile biological cells can increase invasion by malignant ones.^[ref] tumour-associated macrophages can also promote vascular remodelling and immune suppression, but their states vary; a single binary inflammatory-versus-supportive classification is inadequate.

The vascular compartment is another target. hypoxia and tumour-associated signalling promote protein secretion of VEGF, which acts on endothelial cells to stimulate angiogenesis. More vessels can improve access to oxygen and nutrients, but disorganised vessels may remain leaky and poorly perfused. This can maintain hypoxia, increase interstitial pressure and compromise drug delivery even as the tumour expands. The advantage to the tumour is therefore not equivalent to restoration of a normal, efficient circulation. Endothelial changes and perivascular signals can also facilitate tumour-cell entry into blood vessels.

Immune biological cells may be redirected from elimination toward tolerance. Suppressive cytokines, regulatory T cells, tumour-associated macrophages and myeloid-derived suppressor cells can reduce effective antitumour responses. Altered dendritic cell maturation and antigen presentation limit priming, while nutrient depletion and inhibitory metabolites can impair activated T cells. Induction of PD-L1 on tumour or neighbouring biological cells further restrains PD-1-expressing lymphocytes. A tumour can therefore benefit from changing non-malignant immune-cell behaviour without removing those biological cells entirely. Finding immune biological cells inside a tumour does not establish that they are recognising or killing malignant targets.

The same logic can operate at a distance. Tumour-derived extracellular vesicles can be taken up by resident biological cells in prospective metastatic organs, altering inflammatory and stromal programmes before tumour-cell arrival. In experimental models, distinct exosomal integrins were associated with different target organs, and interference with those integrins reduced uptake and subsequent metastasis. Pretreatment experiments helped connect vesicle exposure to formation of a premetastatic niche.^[ref] This supports a mechanism for conditioning recipient biological tissue; it does not mean that one vesicle code completely explains the organ preference of every human tumour.

Reprogramming also includes metabolic cooperation. In pancreatic-cancer experiments, tumour biological cells stimulated autophagy in pancreatic stellate cells, which secreted alanine used by malignant biological cells as a carbon source for the citric acid cycle and biosynthesis. Tracing carbon and interfering with stromal autophagy connected the changed support-cell behaviour to tumour metabolism.^[ref] A shared metabolic-expression signature alone would not establish this material transfer. More generally, to establish a specific transfer, trace labelled substrates into recipient metabolites and biomass, distinguish exchange from independent use of the same nutrient, and block the proposed transport step with rescue by the downstream product. The tumour's advantage should be measured as survival, expansion or invasion under defined conditions.

A general causal design would compare tumour-conditioned and control-conditioned media on purified recipient biological cells, with matched biological cell numbers and viability, then wash and retest recipients to distinguish a persistent state from residual secreted factors. Ligand deletion in tumour biological cells, receptor deletion in recipients and recipient-specific rescue identify directionality. Add-back experiments, direct-contact versus barrier cultures and spatial lineage labels distinguish soluble signals, matrix effects and replacement by contaminating malignant biological cells. In vivo, use cell-type-specific interventions and immune-competent models where immune suppression is the proposed mechanism; a lymphocyte-deficient xenograft cannot establish the full immune interaction.

Importantly, supporting biological cells can also restrain disease. Depletion of alpha-smooth-muscle-actin-positive myofibroblasts in a pancreatic-cancer mouse model reduced fibrosis yet accelerated aggressive disease and immune suppression. The result shows that removing a conspicuous stromal component can eliminate protective functions as well as supportive ones.^[ref] The tumour's advantage emerges from particular reciprocal interactions, so the relevant question is which cell state and function are altered, rather than whether all surrounding normal biological cells are uniformly harmful.

A pericyte is a vessel-associated biological cell located along the outside of small blood vessels, closely associated with endothelial cells. Pericytes help regulate vessel maturation and barrier properties. In mice with reduced pericyte coverage, vascular permeability and transport across the blood-brain barrier change; this connects a surrounding support cell to the function of the endothelial cell barrier. Coverage, anatomical location and functional evidence should be considered together when identifying pericytes. ^[ref]

The rat dorsal air sac assay is an experimental bioassay of angiogenesis in which locally presented material is evaluated by the vascular response of tissue bordering a dorsal air space. It was used to test whether material derived from tumours could promote new blood vessels, connecting biochemical separation with a visible biological effect.

In the 1971 study by Judah Folkman, Ezio Merler, Charles Abernathy and Gretchen Williams, early experiments used membrane chambers containing live tumour cells. For testing separated material, the apparatus used silicone tubing with side openings covered by a short membrane sleeve. That sleeve acted as a diffusing wick, not as a filter. After 48 hours the vascular response was inspected with a stereomicroscope at $20\times$ magnification, followed by collection of sections for histology.^[ref]

The investigators graded vascular proliferation from 0 to 5+. Their illustrations show a wick without the active preparation as a negative control and progressively stronger vascular responses to active material.^[ref] The scientific question is whether the preparation alters the vascular response relative to an appropriate control. A visible response is not automatically a count of endothelial cells, a measured cell proliferation rate or evidence of functional perfusion.

An original scoring example shows why numerical coding must follow the measurement. Suppose one group receives grades 1, 1 and 4, and another receives 2, 2 and 2. Both arithmetic means are 2, although the response patterns differ. Moreover, the ordered relabeling $1\mapsto 1$, $2\mapsto 2$, $4\mapsto 10$ preserves the ranking but changes those means to 4 and 2. An ordered grade alone therefore does not define an interval scale on which differences have a fixed physical meaning. This example is not a reconstruction of the historical observations.

A useful contemporary comparison would specify the test material, solvent control, observation time and scoring rule, and keep the observer unaware of group assignment. Histology and explicit vessel measurements can help distinguish new vascular growth from dilation or local tissue disturbance. Such refinements answer additional measurement questions; this assay does not by itself identify a single angiogenic molecule or demonstrate a treatment effect in human cancer.

Sandrine De Seranno investigated signalling between vascular endothelial cells and glial cells in the neuroendocrine brain. A 2004 study combined purified rat median eminence endothelial cells with cultured tanycytes, identifying nitric oxide-dependent changes in the actin cytoskeleton.^[ref]

Electron microscopy complemented the culture manipulation: stimulating endogenous nitric oxide release changed how glial endings and GnRH-containing axons approached the vascular surface. The work connected a diffusible signal with altered cellular geometry at a neurovascular interface.^[ref]

A tanycyte is a specialized ependymal cell and glial cell of the hypothalamus. Its body can line the third ventricle, while a long process extends toward underlying tissue. In the median eminence, tanycytic endings surround neurosecretory terminals near blood vessels.^[ref]

In cultured rat tanycytes, signals from endothelial cells altered actin organization through nitric oxide.^[ref]

This supplies an illuminating example of structural regulation: a glial cell can change the geometry around a neuron's ending without changing the ending's identity. Evidence for one such interaction does not establish identical functions for every tanycyte subtype.

Tissue engineering uses biological cells, engineered environments and material structures to build or restore tissue-like function. A construct must do more than resemble the shape of a tissue: its cells need suitable surroundings, and the resulting structure must perform the intended biological or mechanical task. The field lies within biomedical engineering, whose scope includes engineering methods applied to biological materials and systems.^[ref]

One approach seeds cells onto a tissue-engineering scaffold that provides an initial geometry and attachment environment. The cells can deposit extracellular matrix while the construct is maintained under controlled culture conditions. A bioreactor can supply nutrients and impose a defined mechanical environment. These roles should be distinguished: a scaffold’s initial strength, the matrix produced by the cells and the mature construct’s function need not be identical.

A motivating primary experiment is the 1999 report of arteries grown from vascular smooth muscle cells and endothelial cells. Bovine vessels were cultured under pulsatile conditions, then assessed for rupture strength, suture retention, contraction and cellular differentiation. The study also reported implantation in miniature swine, with a finite follow-up observation. The combination of mechanical and biological measurements illustrates why a tissue-like shape alone is insufficient evidence of function.^[ref]

A simple design calculation shows how size affects cell support. For diffusion with characteristic diffusivity $D$, the diffusion time over distance $L$ scales asFor illustrative $D=10^{-9}{\mathrm{m}}^2{\mathrm{s}}^{-1}$, a $0.1\mathrm{mm}$ distance gives $t_D\sim 10\mathrm{s}$, whereas $1\mathrm{mm}$ gives $t_D\sim 1000\mathrm{s}$. The tenfold increase in distance produces a hundredfold time scale. These chosen values do not establish a survival limit: consumption, binding, boundary concentrations and fluid transport also matter. They explain why scaling up a dense construct introduces a transport problem, rather than merely requiring more cells.

The engineering task is to coordinate transport, cell adhesion, matrix formation, biocompatibility and mechanical demands. An experiment can measure each separately: nutrient conditions, viable-cell distribution, matrix organization and force response. Together those observations test whether the designed environment has produced the intended tissue function.

Tumour angiogenesis is the growth of new blood vessels from pre-existing vessels in response to a tumour and its surrounding tissue. It supplies a route for oxygen and nutrients to reach growing cells. Vessel formation and effective perfusion are distinct: a vascular image alone does not measure the delivery of oxygen to every part of a tumour.

A foundational experiment by Judah Folkman, Ezio Merler, Charles Abernathy and Gretchen Williams tested tumour-derived material in a rat dorsal air sac assay. A membrane wick delivered separated material locally; after 48 hours the investigators inspected the vascular response with a stereoscope and took tissue sections. A wick without the active preparation provided a negative control. The response was graded from 0 to 5+, rather than measured as an absolute endothelial cell count.^[ref] This connected an isolated preparation to a reproducible biological effect. It did not identify a unique modern molecule or establish that inhibiting one signal would cure all cancers.

An original diffusion model explains why access to vessels matters. Approximate a vessel-free tumour as a sphere of radius $R$ with uniform oxygen consumption $q$ per unit volume per unit time. Let $D$ be a constant diffusion coefficient and fix the surface oxygen concentration at $C_s$. At steady state, the diffusion equation with consumption and spherical symmetry becomesFiniteness at the centre removes the singular integration term. Integrating again and imposing $C(R)=C_s$ givesIf a stipulated threshold $C_{\mathrm{crit}}$ is required to avoid hypoxia, the model predictsFor illustration, take $D=2\times 10^{-9}{\mathrm{m}}^2{\mathrm{s}}^{-1}$, $C_s-C_{\mathrm{crit}}=0.05\mathrm{mol}{\mathrm{m}}^{-3}$ and $q=0.01\mathrm{mol}{\mathrm{m}}^{-3}{\mathrm{s}}^{-1}$. The limiting radius is approximately $2.45\times 10^{-4}\mathrm{m}$, or $0.245\mathrm{mm}$. These are chosen model inputs, not measurements from the historical study or a universal size limit. Quadrupling consumption halves the limiting radius. A predicted negative concentration indicates failure of the assumed uniformly consuming viable sphere, not physically negative oxygen.

The calculation isolates a transport constraint; it does not model vessel branching, changing consumption or delivery by flowing blood. Signals such as vascular endothelial growth factor can influence endothelial cells, but their action and the resulting perfusion require biological measurements beyond this spherical model.